Nephritis affects 30-60% of adults and up to 70% of children with systemic lupus erythematosus (SLE), and is characterized by the glomerular deposition of immune complexes and an ensuing inflammatory response. Glomerular disease is classified by use of light microscopy into five histological subtypes, of which class III (focal proliferative), class IV (diffuse proliferative) and class V (membranous) nephritis have the potential to cause long-term damage; further histological classification is based on composite measures to score active inflammation and chronic scarring [1] [2] [3] [4] [5] . Although this classification scheme drives therapeutic decision-making, it does not adequately predict which patients will respond to therapy 3, 6, 7 , indicating that additional phenotyping focused on mechanisms of tissue injury is required. In addition, patients in clinical remission can exhibit progressive inflammation and fibrosis in samples from repeated renal biopsies, suggesting that improved disease monitoring could prevent undertreatment of subclinical disease 8, 9 . Although advances in immunosuppressive treatment regimens and general medical care have eliminated most of the differences in long-term outcomes between proliferative and membranous lupus nephritis 7, 10, 11 , the rate of complete remission for proliferative disease remains <50% [12] [13] [14] , and up to 40% of patients with stage III-V lupus nephritis still develop some degree of renal impairment 11, 14 . This failure of immunosuppressive agents to adequately treat lupus nephritis, even in the setting of well-monitored clinical trials, reflects an incomplete understanding of disease pathogenesis. Either immunecell proliferation is not the only relevant cause of renal injury, or a therapeutic time window exists after which this type of intervention is no longer effective.
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In the first section of this Review, I discuss the current knowledge of lupus nephritis pathogenesis, including disease initiation by immune complexes, activation of the immune system in the kidney, and the responses of renal parenchymal cells to this insult. In the second part I discuss approaches to identifying new pathogenic mechanisms, and review alternate ways to classify and monitor disease that include molecular and proteomic analyses. Finally, I address how these concepts could lead to improved therapies.
Mechanisms of renal damage

Initiation of inflammation by immune complexes
Lupus nephritis is initiated in most cases by the glomerular deposition of IgG and complement. Rarely, nephritis can occur in the absence of immune complexes, presumably as a result of direct damage to the kidney by soluble inflammatory mediators 15 . Sources of immune complexes include circulating anti-nuclear, anti-C1q, and crossreactive anti-glomerular autoantibodies [16] [17] [18] [19] [20] , opsonized apoptotic particles, microparticles, and neutro phil extracellular traps (NETs) 21, 22 . Particulate DNA such as that within NETs can be resistant to digestion by DNAses anti-DNA activity, not all anti-DNA antibodies are patho genic. Furthermore, non-DNA-binding antibodies, some arising in situ, also contribute to renal disease 24, 25 . This heterogeneity of renal-depositing antibodies limits the ability of serum antibody profiles to predict flares 26 .
Immune complexes initiate renal damage by several mechanisms (FIG. 1) . Complexes that deposit in the subendothelium injure endothelial cells and are the hallmark of class III and IV proliferative disease. These deposits have access to the vascular space and can activate circulating myeloid cells that express Fc receptors, enabling them to infiltrate the renal tissue 27 . By contrast, sub epithelial deposits, found in class V disease, injure podo cytes but elicit a less severe inflammatory response than subendothelial deposits, as they contact only the urinary space. If the glomerular basement membrane ruptures, however, these subepithelial immune complexes can then access the whole glomerulus. Immune deposits can initiate the complement cascade, or they can directly activate intrinsic glomerular cells 28, 29 , inducing the release of inflammatory chemokines and cytokines. Complexes containing nucleic acids additionally activate intra cellular Toll-like receptors (TLRs), thereby enhancing the inflammatory response 30, 31 .
Immune mechanisms of tissue injury Soluble inflammatory mediators. As a consequence of deposition of immune complexes, a large variety of inflammatory mediators is produced in nephritic kidneys, with the immune response spreading to include more inflammatory mediators as disease progresses 28, 32 . Several cytokines and chemokines produced locally that contribute to inflammatory damage, the absence or inhibition of which greatly attenuates disease activity, have been identified. Examples include CC-chemokine ligand 2 (CCL2), a chemokine expressed early in the glomerulo nephritis process, and TNF, which is expressed at onset of proteinuria 33, 34 . A type I inter feron signature is also a feature of nephritic kidneys 35, 36 . Interferon has multiple detrimental effects on the kidneys, including vascular rarefaction and injury to glomer ular parietal cells and podocytes 37, 38 . Once tissue injury occurs, soluble products released from injured cells amplify the inflammatory response by stimulating extra cellular and intracellular innate immune receptors [39] [40] [41] [42] [43] . Podocytes, for example, are sensitive to TLR-mediated signals and other inflammatory mediators such as nitric oxide, which induce effacement of foot processes and podocyte loss 44 . Nevertheless, not all renal inflammatory mediators are necessary for the inflammatory process. For example, IL-17 deficiency alters the course of lupus nephritis only in some disease models in which T helper (T H )17 cells infiltrate the kidneys 45, 46 . Thus, targeting single inflammatory mediators might not be sufficient to reverse the established renal inflammatory response that becomes more complex over time.
Cellular infiltrates.
Inflammatory cells can infiltrate the kidney through glomerular or interstitial blood vessels. The anatomic organization of these infiltrates is quite vari able: they might consist of scattered cells, disorganized aggregates or, rarely, organized structures containing germinal centres 47 . There is also evidence of in situ activation of pathogenic adaptive immune responses to degraded or modified renal antigens. Both B cells and T cells found in nephritic kidneys are clonally expanded, and the same T-cell expansions have been detected in the peripheral blood of patients with lupus nephritis 48, 49 . Multiple T-cell cytokines such as IFN-γ, IL-21 and IL-17 have also been detected in nephritic kidneys 50 , and T cells are present in the urine of patients with lupus nephritis 51 . In a small exploratory study, clonal CD8 T-cell infiltrates were found adjacent to epithelial cells in biopsy samples from nephritic kidneys and were associated with progressive disease, suggesting these T cells have an effector function elicited by local antigens 49 . Strikingly, a measurable proportion of B cells derived from renal biopsy samples of lupus nephritis patients recognize vimentin, an intracellular structural protein that is cleaved and extruded from apoptotic cells 48 . Increasing serum titres of anti-vimentin antibodies are associated with decreasing glomerular filtration rate and increasing tubulointerstitial damage in other forms of chronic kidney disease (CKD), and are similarly associated with severe interstitial disease in lupus nephritis 48, 52 . Autoantibodies to annexin A1 and α-enolase have also been detected in nephritic kidneys 53 . These local adaptive immune responses could amplify inflammation independently of systemic autoimmunity.
Macrophages have a central role in both renal injury and repair. Infiltration of nephritic kidneys by macrophages, particularly when detected at repeat biopsy, is associated with poor prognosis [54] [55] [56] . Both infiltrating inflammatory macrophages and resident interstitial macrophages can be present in diseased kidneys 55, 57, 58 . Macrophages recruited from the peripheral blood are proinflammatory during acute inflammation, but can then switch to a reparative phenotype, thereby enhancing the resolution of inflammation 55, 59 . Resident interstitial macrophages might have self-renewal properties 60 , and in mouse models of chronic lupus nephritis these cells increase in number, become activated, and acquire matrix metalloproteinase and cathepsin activity, suggesting that they contribute to aberrant tissue remodelling 32, 57 . It is increasingly recognized that several types of dendritic cells (DCs) also infiltrate the kidneys during lupus nephritis 61 , potentially propagating local adaptive immune responses 62 . Importantly, an increase in numbers of both CD141 high DCs and myeloid DCs is observed in human glomerulonephritis biopsy samples, and this increase correlates with fibrosis 63 .
Non-immune mechanisms of tissue injury
Several lines of evidence suggest that non-immune mechanisms of renal damage need to be therapeutically addressed in lupus nephritis. First, many patients do not adequately respond to immunological interventions. Second, achieving remission can take months, during which time damage might continue to accrue. Third, progression can occur even if systemic autoimmunity is controlled. Although the role of each intrinsic renal cell type during the stages of injury and repair is still not fully understood, some general mechanisms of CKD should also be applicable to lupus nephritis (FIG. 2) .
Disruption of cell-cell interactions. Maintenance of the complex structure of the nephron requires cell-cell interactions 64 (FIG. 1) . In the glomerulus, mesangial cells are in direct contact with endothelial cells 65 . Mesangial cells sequester latent transforming growth factor (TGF)-β, preventing TGF-β-mediated damage to endothelial cells 66 . Endothelial cells produce platelet-derived growth factor subunit B (PDGF-B); the interaction of this growth factor with its receptor PDGFR-β on mesangial cells is required for glomerular development. Expression of PDGF isoforms is upregulated in many forms of renal injury, causing mesangial hyperproliferation, extracellular matrix (ECM) production, cytokine and chemokine release, and renal fibrosis 67 . Podocytes and endothelial cells also interact by bidirectional diffusion of cytokines and growth factors through the glomerular basement membrane 65 . Podocytes secrete angiopoietin (ANG)-1 and vascular endothelial growth factor A (VEGF-A), which support endothelial-cell survival; loss of renal VEGF-A charac terizes lupus nephritis both in human disease and mouse models and distinguishes lupus nephritis from other forms of CKD 36 . In diseased tissue, both activated glom erular endothelial cells and damaged podocytes release endothelin-1 that amplifies glomerular injury by causing mitochondrial stress 68 . Since adult podocytes have limited regenerative capacity, loss of podocytes eventually leads to glomerulosclerosis. As nephrons are lost, compensatory mechanisms cause a rise in intraglom erular pressure and glomerular stress in the remaining nephrons 69 . A cell type that has received much attention in the past 5 years is the pericyte, which comes into contact and shares a basement membrane with capillary endothelial cells. Pericytes secrete VEGF-A, chemokines and other inflammatory mediators, help maintain endothelial-cell quiescence, contribute to the basement membrane, and regulate both medullary blood flow and cell traffic through the endothelial barrier during inflammation [70] [71] [72] . Mesangial cells are the pericytes of the glomerulus and the interstitium has its own pericyte net work attached to tubular capillaries. During inflammation, these interstitial pericytes rapidly dissociate from tubular capillaries and migrate into the interstitial space where they differentiate into myofibrobasts 73 .
Abnormal vascular function and tissue hypoxia.
Glomerular endothelial cells are coated with a glycocalyx layer that forms a crucial barrier to protein loss 74 ; this barrier can be degraded by the enzyme heparanase, which is induced by endothelial hypoxic stress 75 . As peri cytes dissociate from capillaries and VEGF-A production by these cells diminishes, the capacity for angiogenesis and capillary repair is lost, leading to capillary rarefaction in both the glomerulus and the interstitium 73, 76 . Other disturbances of angio genesis reported in lupus nephritis include a decrease in the ratio of pro angiogenic ANG-1 to anti-angiogenic ANG-2, down regulation of the angio genic fibroblast growth factor (FGF)-2, an increase in expression of the VEGF inhib itor ADAMTS-1, and alter ations in levels of endothelial nitric oxide synthase 70, [77] [78] [79] . In a mouse model of lupus nephritis, downregulation of VEGF-A and FGF-2 genes persists even after induction of complete remission, suggesting that vascular injury is not completely reversible 32 . Some areas of the kidney, especially the medulla, maintain a low partial oxygen pressure even under normal physiological conditions and are sensitive to hypoxia. The interstitial blood supply comes from postglomerular blood vessels, so glomerular hyper tension and scler osis can cause interstitial ischaemia. Loss of VEGF-A, oxidative stress due to inflammation, increased energy demands, endothelial-cell injury by cytokines, enhanced endothelin release, hypertension and anaemia all contribute to hypoxia [80] [81] [82] ; the relative contribution of each of these mechanisms is not well understood. Tubular dysfunction and atrophy. Ischaemia, hypertension or failed regeneration contribute to atrophy of tubular epithelial cells; such injury promotes both interstitial immune-cell infiltration and fibrosis. A 2015 study in an animal model showed that injured renal tubular cells have a defect in fatty acid oxidation that causes mitochondrial dysfunction, reprogrammes the cells to a profibrotic phenotype, and contributes to their death 83 . The defect can be reversed by tubule-specific expression of the mitochondrial biogenesis regulator PGC-1α (peroxisome proliferator-activated receptor-γ (PPAR-γ) co-activator 1α). Importantly, human fibrotic kidneys have a similar alteration in tubular fatty acid metabolism, suggesting a potential new therapeutic approach to prevent terminal renal failure due to renal tubular death 83, 84 .
Renal fibrosis and progression to CKD. Renal fibrosis is associated with poor prognosis in lupus nephritis, as is the case with CKD in general. The extent of fibrosis is determined by the balance of ECM production with enzyme-mediated ECM breakdown and turnover 85 . Mesangial cells are the classical myofibroblasts in the glom erulus, but parietal epithelial cells and podo cytes might also contribute to the fibroblast pool 85 . In the interstitium, pericytes and resident fibroblasts are the major sources of myofibroblasts, which produce ECM, inhibitors of matrix metalloproteinases, and colla gen 86 . Both tissue-resident macrophages and tubular epithelial cells produce growth factors that support myofibroblast differ entiation, including TGF-β, PDGF and connective tissue growth factor (CTGF) 87, 88 . These factors are balanced by local antifibrotic factors such as the TGF-β antagonists bone morphogenetic protein 7 (BMP-7) and hepatocyte growth factor 87, 89 . In addition, cytokines, chemokines, matrix proteins, procoagulants and remodelling enzymes produced by inflammatory cells, tubular cells and macrophages contribute to a profibrotic microenvironment 90 . Although it has not been shown unequivocally that an area of fibrosis will damage adjacent healthy nephrons 89 , several lines of evidence indicate that fibrosis can ampli fy renal damage. Fibroblasts can contribute to tissue injury by producing proinflammatory mediators 91 . Fibrotic tissue can disrupt normal anatomic structures and interfere with oxygen diffusion, thus exacerbating hypoxia 85 . In addition, epigenetic changes can reprogramme fibroblasts to maintain their profibrotic state even after inflammation has resolved [92] [93] [94] . One epi genetic change that has received considerable attention is the upregulation of microRNA (miR)-21, which protects against acute renal inflammation and damage but also exacerbates fibrosis 95, 96 .
Identifying novel pathways of disease Improving therapy for SLE is likely to require disease classification based on pathogenic mechanisms. Some of these mechanisms will be common to most patients, some might be stage-specific, and others might apply to smaller patient subgroups or even individual patients. Several approaches to identify shared pathogenic pathways have been explored.
Clinical and epidemiologic studies
Factors associated with poor outcome in lupus nephritis are shown in BOX 1 (REFS 11, 97, 98) . Long-term outcome depends on the degree of response to treatment, with reso lution of proteinuria being the best surrogate marker of a favourable prognosis 99, 100 . The severity of renal damage at presentation, manifested by serum creatinine level and the extent of interstitial inflammation and fibrosis, strongly influences the response to treatment 56, [101] [102] [103] . These data support the need for improved monitoring of individuals at high risk of severe disease, and suggest that early detection of lupus nephritis and prompt inter vention will improve outcomes. Not surprisingly, non-response to therapy, recurrent flares and the presence of residual inflammation or fibrosis at repeat biopsy are associated with a poorer prognosis 56, 102, 103 . Repeat biopsies are not routinely performed, but could be useful to guide tapering of treatment or changes in maintenance therapies, or both.
Importantly, epidemiological data from Medicaid patients treated in the USA from 2000-2006 has shown poor quality of care in uninsured individuals and in geographic areas where access to ambulatory care is limited, indicating a substantial effect of healthcare policy and healthcare access on lupus nephritis outcomes 104 . Similar results have been shown in other countries 105 . Unless this public health issue is addressed, it seems unlikely that outcomes will be improved by medical management alone. 
Genetic analyses Genome-wide methods.
A recent meta-analysis of three genome-wide association studies (GWAS) identified several inherited polymorphisms that predispose an individual to initiation of lupus nephritis, including markers localized to PDGFRA, the glucose transporter locus SLC5A11, and the gene HAS2 encoding hyaluronan synthase 2, which is involved in ECM formation 106 . Other genes associated with risk of lupus nephritis include TNIP1 (also known as ABIN-1), TNFSF4, STAT4 , ITGAM, kallikrein genes, and weak-binding FCGR3A alleles [107] [108] [109] [110] [111] [112] [113] . These results suggest a link between inflammation and lupus nephritis, as well as a contribution from pathways that regulate the renal response to inflammation and injury. However, the relative risk associated with most of these genetic variants is low, and some are relevant only in certain ethnic populations, making it challenging to generate a clinically meaningful genetic risk-prediction test. The function of the various poly morphisms will need to be determined in order to understand their clinical relevance.
Only a few small studies have addressed the genetic risk for increased disease severity in patients with lupus nephritis. Polymorphisms in APOL1 and MYH9 confer an increased risk of renal failure in other chronic renal diseases, and seem to confer a modest increase in risk of lupus nephritis progression that might be dependent on ethnicity [114] [115] [116] . No studies have addressed the genetic basis for responsiveness to therapy.
Local epigenetic changes.
The epigenetic landscape of renal injury is only just starting to be described, particularly interstitial injury 117, 118 . Examples of local epigenetic changes relevant to lupus nephritis include chromatin structure modifications that regulate the production of CCL2 and TNF, DNA demethylation that regulates C3 production, and histone acetylation that regulates the expression of PDGF and profibrotic genes 118 . Histone deacetylase inhibitors alleviate progression in multiple models of renal injury and fibrosis by preventing cytokine release and cell apoptosis and by inducing expression of the protective molecule BMP-7 (REFS 119,120). Epigenetic changes can also be mediated by noncoding RNAs. TGF-β induces several mi RNAs that enhance expression of profibrotic genes while also inhibiting mi RNAs that are protective 95, 96 . The utility of blood and urine miRNA signatures as biomarkers for lupus nephritis is now being examined 121, 122 .
Molecular and proteomic phenotyping
Molecular and proteomic phenotyping of the kidney or urine could identify the immunological and/or injury process affecting an individual patient, and provide biomarkers to improve patient stratification for clinical trials and a more rational therapeutic approach.
Molecular profiling of nephritic kidneys.
Several studies have characterized transcriptional signatures of immune-cell infiltration and activation, ECM formation and fibrosis, endothelial-cell activation, fibrinolysis, mitochondrial dysfunction, and tubular injury that are associated with lupus nephritis 36, 123, 124 . Because human kidney samples from pre-nephritis and repeat biopsies are rarely available, mouse models have been useful for characterizing renal molecular profiles at sequential disease stages. Overlay of data from animal studies onto data from human biopsies enables the identification of pathways in mouse models relevant to human disease. Using transcriptome analysis in NZB/NZW lupus-prone mice, my group identified two main gene clusters that are dynamically regulated during disease progression; the first profile is detected at proteinuria onset and reflects the inflammatory component of nephritis, whereas the second occurs during established proteinuria and reflects the mitochondrial and metabolic signature of chronic disease. Remission-induction therapy administered promptly after onset of nephritis reverses most of this abnormal gene expression, but we noted that the mitochondrial and metabolic signature recurred before clinical relapse, perhaps reflecting an increased propensity to tissue hypoxia conferred by the initial tissue insult 32 . By monitoring mice from remission to relapse, we further identified podocyte loss, renal tubular dysfunction, endothelial-cell activation and tissue remodelling as the functional features associated with progression to renal failure 32 . Some of these processes could be resistant to standard immune suppression 36, 125 . One important observation in mice is that glomerular disease does not always progress to tubular and endothelial dysfunction 126, 127 . For example, lupus-prone mice deficient in B cell-activating factor (BAFF, also known as TNF ligand superfamily member 13B) or treated with BAFF blockade have autoantibodies, glomerulo nephritis and interstitial inflammatory infiltrates but do not die of renal failure 32, 126 . Similarly, a genetic model has been generated in which acute glomerular injury occurs, but progression to CKD does not 128 . How the transition from renal inflammation to renal failure is regulated is not completely understood [129] [130] [131] and is an important knowledge gap [121] [122] [123] . In addition, several models of lupus nephritis exist in which renal deposition of immune complexes does not induce the recruitment of effector cells; these models include myeloid-cell deficiency of Fc receptors, CCL2 deficiency and intense co-stimulatory blockade 27, 132, 133 . These studies, in sum, suggest several opportunities for therapeutic intervention targeting the effector response in the kidney, regardless of systemic autoimmunity.
A problem with the interpretation of molecular profiles of whole tissues is that the signatures are biased towards the most frequent cell types and towards infiltrating cells that are rare in normal kidneys. The only way to overcome these biases is to study each cell type individually. No studies of this kind have as yet been performed in human nephritic tissue, and the data from mouse models is quite limited.
Molecular studies in both mice and humans have suggested that macrophages and DCs are key players in the development of lupus nephritis 36 . Comparative molecular profiling of isolated renal macrophages from young and nephritic NZB/NZW mice and NZW/BXSB mice 36, 57 revealed that several functional pathways are upregulated 
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Lymphoid aggregates T REG cells Nature Reviews | Rheumatology in macrophages from nephritic mice including the alternate complement pathway, cell adhesion, phagocytosis and efferocytosis, Fc receptor signalling, the nucleic acid sensing pathway, and tissue repair. Pathways that are downregulated include fatty-acid metabolism and angio genesis. This profile suggests aberrant reso lution of inflammation, which could be driven by ongoing immune complex deposition and/or tissue damage.
Whether the reparative function of macro phages could be harnessed for optimal tissue repair without ensuing fibrosis remains to be determined.
Proteomic analysis of nephritic kidneys.
Proteomic analysis of kidneys has been challenging due to the limited amount of tissue available and the inability to detect small or low-abundance proteins; however, the feasibility of this approach is increasing with new technical advances. A proteomic analysis of human lupus glomeruli revealed loss of podocyte proteins, activation of the alternate complement pathway, loss of antioxidants and downregulation of normal metabolic pathways, consistent with the findings of the molecular studies described previously in this Review 134, 135 . Analyses of biopsy samples from patients with proliferative lupus neph ritis using a targeted set of 500 immune-response genes showed that activation of interferon pathways, pro duction of IL-10 and T-cell and B-cell signalling path ways are associated with lack of response to therapy 6 . These data are consistent with the clinical observation that the presence of interstitial infiltrates are associated with poor prognosis. It is also becoming clear that variability in the renal proteome can occur within a given class of glomerular disease, suggesting the potential for subclassification based on proteomic analysis 136 . In sum, preliminary molecular and proteomic studies of lupus nephritis kidneys have extended mechanistic knowledge beyond that obtained from histologic data by identifying two phases of disease that are characterized by inflammation and metabolic dysfunction, respectively; these studies have also identified both shared and unique effector signatures among mouse models, and have identified a number of checkpoints along the path to irreversible renal damage that could be targets for new therapies. The molecular studies have been less successful at identifying the earliest features of lupus nephritis than at defining pathways and biomarkers for progression of established disease as expression of only a few genes is upregulated in the kidneys before the onset of protein uria 32 ; a proportion of these genes is associated with steroid and lipid metabolism. Proteomic and metabo lomic studies might be more suitable for detecting such early changes 137, 138 .
Analysis of urine.
Longitudinal monitoring of urine offers insight into kidney function that could inform treatment decisions. The technical challenges inherent to this approach have been reviewed elsewhere 136 . The major clinical use of urine proteomics so far has been to identify biomarkers that either predict an impending renal flare 6, 139 or indicate response to therapy. Several longi tudinal studies have evaluated single urinary bio markers including the chemokine CCL2, the tubular marker neutrophil gelatinase-associated lipocalin (also known as lipocalin-2), the acute-phase protein hepcidin and the TNF-like molecule TWEAK (reviewed else where 136, 140 ). These studies are preliminary and the bio markers have not yet been reliably reproduced or tested in the setting of a clinical trial. Panels that combine these and other potential biomarkers identified in cross-sectional studies might have a higher predictive value than single analytes alone.
It is important to note that cells and microparticles of cells are also shed into the urine during inflammation. This circumstance could be exploited for the discovery of other protein and RNA-based biomarkers, and for early detection of podocyte loss.
Preclinical therapeutic studies.
A final approach to identifying key pathways in lupus nephritis is to identify potentially pathogenic molecules on the basis of their known biology and then test their role in pre clinical models by either genetic depletion or therapeutic targeting. This approach is often successful when the appropriate preclinical model is used and the treatment is timed either before or at the first presentation of lupus neph ritis 141 . Nevertheless, this approach is proving cumber some and expensive in human lupus nephritis and has been hampered by the primitiveness of disease phenotyping, the confounding effects of standard medications such as glucocorticoids, and the absence of a uniformly accepted definition of renal outcome 142 . When choosing molecular targets for clinical trials in humans, it is important to consider the sometimes opposing effects of pleiotropic immune pathways and cytokines on systemic immunity versus local effector responses. Genetic deficiencies of TNF, TGF-β, components of the innate pathway (such as TLR-9, STING and NADPH oxidase 2), and inflammasome components (NLRP3 and ASC) all induce or exacerbate autoimmunity in mice [143] [144] [145] . This disease exacerbation could be attributable to loss of regulatory functions of these proteins or to diminished capacity to fully control infectious insults. On the other hand, both TNF and TGF-β are highly expressed in inflamed kidneys, and their inhibition at this stage of disease improves disease outcomes in mouse models 34, 146 . TNF inhibition does indeed improve chronic lupus nephritis in patients without inducing systemic flares, although its clinical utility has been limited by other toxicities 147 . Nevertheless, targeting these types of pathways will require a cautious approach.
Implications for treatment
Targeting systemic autoimmunity Given the role of systemic autoimmunity in the initiation of lupus nephritis, prevention should be a major focus of management. Indeed, in mouse models of lupus, nephritis can be completely prevented by immunosuppressive interventions that prevent the renal deposition of auto antibodies, or by genetic manipulations that prevent tissue responses to immune complex deposition 148 . However, many obstacles hinder the use of a similar approach in humans, including the heterogeneity of immune responses between individual patients, the lack of non invasive monitoring tools for early detection of nephritis, the potential toxicity of new therapies in patients with quiescent disease, and the expense of time-to-flare studies, which require large cohorts.
Once disease onset occurs, there may only be a limited amount of time before disease mechanisms that are insensitive to preventive strategies arise. In mice, prevention of disease onset is much easier than treating established disease with drugs that target T cells or B cells and, in some mouse strains, combinations of drugs are needed to induce remission 141, 148 . Delays in diagnosis and treatment could result in the recruitment of inflammatory amplification circuits or the onset of metabolic or structural changes in the kidneys that are difficult to reverse with immunotherapy. Variability in treatment responses could also arise from intrinsic differences between patients. Considerably different responses to immunotherapy are observed in different mouse models of lupus nephritis even when intervention is initiated at disease onset 141 ; this may reflect hetero geneity in the severity of inflammation, the relative involvement of innate versus adaptive immune pathways, the balance of inflammation versus metabolic abnormalities, and the extent of tissue hypoxia, nephron loss and tubular regenerative capacity (FIG. 3) .
Although treatment with biologic agents has not yet been successful in patients with lupus nephritis 149, 150 , many new approaches remain to be tested 149, 151 . Obvious targets for biologic therapies include key cytokines expressed in inflamed kidneys, such as IL-1, IL-6, macro phage colony-stimulating factor, IFN-γ, type I interferon, BAFF, IL-17 and IL-21, signalling pathways such as tyro sine kinases, co-stimulatory molecules such as ICOS, and effector molecules such as those in the complement pathway (reviewed elsewhere 152 ). Chemokines are also appealing targets but, despite extensive effort, research in this area has not yet successfully translated to therapies for human autoimmune disease 153, 154 . One successful pilot approach has been to deplete plasma cells with a proteasome inhibitor, clearing immune complexes and allowing the kidney to heal 155 . Nevertheless, the overall experience with immune suppression shows that non-immunebased approaches to preventing disease progression 156 also need to be considered to optimize the resolution and repair process
. The combined targeting of immune and non-immune mechanisms is still in its infancy, but new approaches are being tested that might also be applicable to lupus nephritis.
Targeting endothelial cell dysfunction
An improved understanding of the mechanisms of endothelial dysfunction and hypoxia could lead to novel therapies. Endothelial glycocalyx deterioration can be prevented by angiotensin-2 inhibition, and mycopheno late can inhibit PDGF-B production 157 . Angiotensin-converting enzyme (ACE) inhibitors also reduce endothelial activation by increasing nitric oxide production independently of their anti-hypertensive effects 78 . Podocytes lacking both endothelin receptors are protected from damage in animal models of diabetes, and an endothelin antagonist reduced proteinuria in patients with diabetic nephropathy 158 . Targeting of VEGF-A 159 or PDGF has proved more challenging because the relationships between angiogenesis, inflammation and fibrosis are still not fully understood. For example, some proangiogenic factors also enhance inflammation or fibrosis 78 and PDGF might be involved in tubular regeneration 87 . In addition, angiogenesis might be detrimental early in disease, helping to mediate glomer ular hypertrophy, before becoming dysfunctional at later stages 78 .
Preventing and reversing renal fibrosis Several strategies for preventing or reversing renal fibrosis are in clinical development, including monoclonal antibodies to TGF-β and CTGF or their downstream signalling pathways, growth factor antagonists such as BMP-7 mimetics, phosphodiesterase inhibitors, and NADPH oxidase inhibitors 87, 160 . Nevertheless, the wide array of potentially profibrotic factors that arise in inflamed kidneys 90 suggest that broad approaches are needed. One exciting new therapeutic area is the prevention of tubular epithelial injury based on a better understanding of the mechanisms of tubular stress. Data from mouse models suggests that pharmacological enhancement of fatty-acid oxidation can protect tubules from death and help prevent fibrosis 83 . Reparative macrophages that arise during the healing phase of acute inflammation may act to reverse early fibrosis by endocytosis and degradation of collagen 161 or by secreting enzymes that break down collagen and ECM. These macrophages can also stimulate tubular epithelial-cell regeneration by a mechanism involving the Wnt pathway 162 . Importantly, however, prolonged exposure to reparative macrophages can cause renal fibrosis or excessive remodelling 163 . Strategies targeting dysfunctional macrophage repair have included antagonism of the interstitial macrophage receptor CCR1 (CC chemokine receptor type 1) and of the resident macrophage receptor CX3CR1 (CX3C chemokine receptor type 1) 164 . More-effective targeting of macrophages will require a better understanding of how their inflammatory, profibrotic and reparative functions are regulated during the various stages of disease.
Conclusions
Progress continues to be made in our understanding of the mechanisms of acute and chronic renal injury as they pertain to lupus nephritis. Although immunosuppressive agents remain the mainstay of treatment, new biologic agents continue to be tested and the development of treatments that protect the kidneys against endothelial and tubular injury and fibrosis could help prevent chronic damage. Progress in the development of new therapies for lupus nephritis will require the formation of relevant consortia, patient and physician engagement in research protocols, improved clinical trial design, improved definitions of renal outcome (which might involve repeat biopsies), testing of molecular and proteomic analyses in clinical trials and, finally, strategies for prevention and treatment based on these results. The most cost-effective current approach involves early recognition of neph ritis 165 followed by prompt intervention and treatment of reversible risk factors. This approach requires access to properly trained health care providers and to medications, and is the necessary foundation upon which individualized care for patients with lupus nephritis can eventually be built.
